Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

[Clinical analysis of therapeutic impact and prognosis of autologous peripheral blood stem cell transplantation in multiple myeloma].

Qu XY, Chen LJ, Miao KR, Zhang R, Lu RN, Liu P, Qian SX, Lu H, Qiu HX, Xu W, Wu HX, Li JY.

Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):352-4. doi: 10.3760/cma.j.issn.0253-2727.2013.04.023. Chinese. No abstract available.

PMID:
23668212
2.

Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma.

Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, Fenske TS, Horowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR.

Biol Blood Marrow Transplant. 2013 Sep;19(9):1368-73. doi: 10.1016/j.bbmt.2013.06.017. Epub 2013 Jun 24.

3.

Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma.

Korthals M, Sehnke N, Kronenwett R, Schroeder T, Strapatsas T, Kobbe G, Haas R, Fenk R.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1109-15. doi: 10.1016/j.bbmt.2013.04.025. Epub 2013 May 2.

4.

[High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience].

Piatkowska-Jakubas B, Wolska-Smoleń T, Mensah-Glanowska P, Hawrylecka D, Szostek M, Walter Z, Skotnicki AB.

Przegl Lek. 2011;68(2):78-81. Polish.

PMID:
21751514
5.

Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation.

Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G, Cremer FW, Lowenthal RM, Huesing J, Fruehauf S, Moehler T, Ho AD, Goldschmidt H.

Eur J Haematol. 2007 Jan;78(1):21-8. Epub 2006 Sep 28.

PMID:
17042762
6.

Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.

Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, Murakami H, Hayashi K, Mina R, Palumbo A, Shimizu K; Japanese Society of Myeloma; European Myeloma Network.

Acta Haematol. 2014;132(2):211-9.

7.

Efficacy of diverse high-dose regimens followed by autologous peripheral blood stem cell transplantation in consecutive multiple myeloma patients: a single-centre analysis over a 12-year period.

Haas PS, Bauchmüller K, Kühnemund A, Finke J, Ihorst G, Engelhardt M.

Ann Hematol. 2006 Mar;85(3):191-3. Epub 2005 Dec 20. No abstract available.

PMID:
16365747
8.

Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.

Alyea E, Weller E, Schlossman R, Canning C, Mauch P, Ng A, Fisher D, Gribben J, Freeman A, Parikh B, Richardson P, Soiffer R, Ritz J, Anderson KC.

Bone Marrow Transplant. 2003 Dec;32(12):1145-51. Review.

PMID:
14647268
9.

Predictive factors for successful salvage high-dose therapy in patients with multiple myeloma relapsing after autologous blood stem cell transplantation.

Fenk R, Liese V, Neubauer F, Bruns I, Kondakci M, Balleisen S, Saure C, Schröder T, Haas R, Kobbe G.

Leuk Lymphoma. 2011 Aug;52(8):1455-62. doi: 10.3109/10428194.2011.575967. Epub 2011 Jun 10.

PMID:
21657961
10.

Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Fabre C, Koscielny S, Mohty M, Fegueux N, Blaise D, Maillard N, Tabrizi R, Michallet M, Socié G, Yakoub-Agha I, Garban F, Uzunov M, François S, Contentin N, Lapusan S, Bourhis JH.

Haematologica. 2012 Apr;97(4):482-90. doi: 10.3324/haematol.2011.049742. Epub 2011 Nov 4.

11.

Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients.

O'Shea D, Giles C, Terpos E, Perz J, Politou M, Sana V, Naresh K, Lampert I, Samson D, Narat S, Kanfer E, Olavarria E, Apperley JF, Rahemtulla A.

Bone Marrow Transplant. 2006 Apr;37(8):731-7.

PMID:
16501593
12.

Autologous stem cell transplantation in myeloma: the St James's Hospital experience, 1997-2003.

Hayden PJ, O'Driscoll A, Gardiner N, Swords R, Sargent J, Ni Ainle F, Fortune A, Murphy PT, Leahy M, Jackson F, Ryan M, Hennessy B, Cahill M, Crotty GM, Enright H, Conneally E, Vandenberghe E, McCann SR, Browne PV.

Ir J Med Sci. 2005 Apr-Jun;174(2):26-32.

PMID:
16094909
13.
14.

Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.

Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S.

Transfusion. 2007 Dec;47(12):2207-16. Epub 2007 Aug 21.

PMID:
17714420
15.

Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.

Corso A, Mangiacavalli S, Cocito F, Pascutto C, Ferretti VV, Pompa A, Ciampichini R, Pochintesta L, Mantovani LG.

PLoS One. 2013 Sep 30;8(9):e75047. doi: 10.1371/journal.pone.0075047. eCollection 2013. Erratum in: PLoS One. 2014;9(1). doi:10.1371/annotation/949c27ad-65b0-4926-8c7b-5a45d67b1be9.

16.

Newly diagnosed multiple myeloma: allograft or autograft?

Gupta D, Kumar L.

Natl Med J India. 2007 Nov-Dec;20(6):300-1. No abstract available.

PMID:
18335797
17.

Impact of response to thalidomide-, lenalidomide- or bortezomib- containing induction therapy on the outcomes of multiple myeloma patients undergoing autologous transplantation.

Awan FT, Osman S, Kochuparambil ST, Gibson L, Remick SC, Abraham J, Craig M, Jillella A, Hamadani M.

Bone Marrow Transplant. 2012 Jan;47(1):146-8. doi: 10.1038/bmt.2011.18. Epub 2011 Feb 28. No abstract available.

PMID:
21358681
18.

Hemophagocytic syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma; successful treatment with high-dose intravenous immunoglobulin.

Ostronoff M, Ostronoff F, Coutinho M, Calixto R, Souto Maior AP, Sucupira A, Florencio R, Tagliari C.

Bone Marrow Transplant. 2006 Apr;37(8):797-8. No abstract available.

PMID:
16518425
20.

Unsuccessful stem cell remobilization for autologous transplantation is predicted by renal impairment and a stem cell yield ≤ 0.5 X 10(6) CD34+ cells/kg at first mobilization.

Hill QA, Pearce R, Cook G.

Bone Marrow Transplant. 2012 Oct;47(10):1372-3. doi: 10.1038/bmt.2012.20. Epub 2012 Feb 20. No abstract available.

PMID:
22343671

Supplemental Content

Support Center